Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Unknown Analyst

Good morning, everyone. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference. For those of you who don’t know me, I’m [ Theresa Capilla ], European pharma research analyst here at Morgan Stanley, and I’m joined by my colleague, Adithya Venkat at MS.

And I’m very pleased to have Richard Francis and Eric Hughes here today, the CEO and Head of R&D of Teva. But thank you very much for joining us.

Richard Francis
President, CEO & Director

Thank you for having us.

Unknown Analyst

So before we get started, please note that this presentation is for Morgan Stanley institutional clients and employees.

For all important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your MS sales rep.

And I apologize for how many times I’m going to say that over the next 30 days. So perhaps we get started, Richard, before we go into detail, perhaps you could start with introductory comments as to where we are in the Teva story today, progress on the Pivot to Growth strategy and the outlook from here.

Richard Francis
President, CEO & Director

Okay. I’ll try and be brief because I could spend the whole time talking about that. So where we are in the story, to answer that first part of the question.

So Pivot to Growth, we started in 2023. It was a 3-part plan: return to growth, accelerate growth and maintain growth. So we’re